San Diego, California and Vancouver, British Columbia, March 22, 2012 – Protox Therapeutics Inc. (TSX: PRX) (“Protox”), a developer of innovative products for the treatment of urological diseases, today announced that Allison Hulme, PhD, Chief Operating Officer and Head of Research & Development, will present at the 11th Annual Needham Healthcare Conference in New York City. Dr. Hulme’s presentation will take place at 3:20 p.m. EDT on Tuesday, April 3, 2012.
A live webcast of the presentation may be accessed via the Protox website www.protoxtherapeutics.com.
Protox Therapeutics is a developer of innovative products for the treatment of urological diseases. Protox’s lead program, PRX302 (PORxin), achieved positive results from its Phase 2b placebo controlled trial called TRIUMPH, to treat benign prostatic hyperplasia (BPH or enlarged prostate). Protox has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan.
For more information, please visit www.protoxtherapuetics.com.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forwardlooking statements are based on Protox’s current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, Protox’s attendance at the conference, business prospects, strategies and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information contact:
646 378 2972